tretazicar has been researched along with nicotinate ribonucleoside in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abrahamson, JA; Biggs, PJ; Friedlos, F; Knox, RJ | 1 |
| Anlezark, GM; Davies, LC; Friedlos, F; Goddard, P; Jarman, M; Knox, RJ; Melton, RG; Sherwood, RF | 1 |
2 other study(ies) available for tretazicar and nicotinate ribonucleoside
| Article | Year |
|---|---|
Potentiation of CB 1954 cytotoxicity by reduced pyridine nucleotides in human tumour cells by stimulation of DT diaphorase activity.
Topics: Antineoplastic Agents; Aziridines; DNA, Neoplasm; Drug Synergism; Humans; Intracellular Fluid; Kinetics; NAD; NAD(P)H Dehydrogenase (Quinone); Niacinamide; Pyridinium Compounds; Ribonucleosides; Stimulation, Chemical; Tumor Cells, Cultured | 1992 |
Virtual cofactors for an Escherichia coli nitroreductase enzyme: relevance to reductively activated prodrugs in antibody directed enzyme prodrug therapy (ADEPT).
Topics: Animals; Antibodies; Aziridines; Escherichia coli; Mice; NAD; Nitroreductases; Oxidation-Reduction; Prodrugs; Pyridinium Compounds; Ribonucleosides; Vitamin K | 1995 |